Using tirzepatide before bariatric surgery to improve outcomes
Official title: Preoperative Tirzepatide for Bariatric Surgery
Run by University of Kentucky · NCT06721507 · Data updated 2026-11-12
This study is testing if taking tirzepatide before weight loss surgery can help patients recover better and have fewer complications after the surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | University of Kentucky Academic / other |
| Locations | 1 site (Lexington, Kentucky) |
| Status | Recruiting |
| Started | March 27, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 14, 2026 |
| Trial ID | NCT06721507 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with a BMI of 45 kg/m2 or higher and obesity-related comorbidities, scheduled for laparoscopic or robotic sleeve gastrectomy.
✕Probably not a fit
Patients with contraindications to tirzepatide or certain medical histories, such as type 1 diabetes or pancreatitis, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates whether administering tirzepatide prior to bariatric surgery can enhance postoperative outcomes for patients. The study aims to evaluate the effects of tirzepatide on inflammatory markers and its correlation with weight loss, metabolic improvements, and surgical complications. Participants will be assigned to either receive tirzepatide or standard care for three months before their scheduled laparoscopic or robotic sleeve gastrectomy. The results could inform future therapeutic guidelines for obesity treatment.
Why it matters
Potential benefit: If successful, this approach could lead to better surgical outcomes and improved health for patients undergoing bariatric surgery.
How similar studies have gone: While the specific use of tirzepatide in this context may be novel, similar studies have shown promising results in using medications to enhance surgical outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * adults who have been enrolled in the multidisciplinary metabolic and bariatric surgery program at the UK HealthCare Weight Loss Surgery Clinic and are scheduled to receive laparoscopic or robotic sleeve gastrectomy, or gastric bypass surgery * BMI greater than or equal to 40 kg/m2 with one or more obesity-related comorbidities * have demonstrated abstinence from any form of nicotine use, confirmed by serum nicotine and metabolite testing * enrollment in the ADORE Bariatric Tissue Bank (IRB #69767) Exclusion Criteria: * any contraindication to the use of tirzepatide (per package insert) * Personal or family history of medullary thyroid carcinoma * Patients with Multiple Endocrine Neoplasm syndrome type 2 * Hypersensitivity to tirzepatide * History of pancreatitis * Type 1 Diabetes * patients with active, untreated or symptomatic cholelithiasis or jaundice * consistent use of a GLP-1 or GLP-1/GIP receptor agonist, over the past 90 days * diagnosed autoimmune disease * current use of immunosuppressive agents or use within the past 30 days * moderate or severe substance use disorder according to DSM-5 criteria * uncontrolled significant psychiatric disorder as assessed by specialized bariatric psychologist * female participant who is pregnant, breast-feeding, or intends to become pregnant with in 1 year following surgery * a prisoner
Where it's running
-
University of Kentucky
Lexington, Kentucky, United States Recruiting
Study contacts
- Principal investigator: Marlene Starr, PhD — University of Kentucky
- Study coordinator: Marlene Starr, PhD
- Email: marlene.starr@uky.edu
- Phone: 859-323-0471
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if same day discharge after bariatric surgery is safe for select patients
This trial tests whether people having sleeve gastrectomy or gastric bypass can go home the same day or should stay at least one night, to see if ER visits within a week differ.
-
Investigating the long-term health effects of obesity treatments on women
This study is trying to see how different obesity treatments affect women's health over time, including their nutrition, bones, muscles, and pregnancy outcomes.
-
15-year outcomes after sleeve gastrectomy in France
This study looks at how people who had sleeve gastrectomy have fared over 15 years to see long-term weight changes and health effects.
-
Mother and baby health after bariatric surgery in pregnancy
This study follows pregnant women who have had bariatric surgery and those who have not to see how nutrition, pregnancy health, and baby outcomes compare.
-
Understanding glucagon and sugar metabolism after meals in people with and without PBH after weight-loss surgery
This study tests how glucagon and post-meal glucose handling differ between people who have post-bariatric surgery hypoglycemia and those who don’t.
-
Collagen Supplements After Sleeve Gastrectomy
This observational study looks to see if taking collagen-containing supplements after sleeve gastrectomy affects muscle mass, body composition, and body image in adults who had bariatric surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.